Influence of Micrococcus, BCG and Related Polysaccharides on the Proliferation of the L1210 Leukaemia

Overview

Journal Br J Cancer

Specialty Oncology

Date 1978 Nov 1

PMID 728349

Citations 1

Authors

R Verloes

G Atassi

P Dumont

L Kanarek

Affiliations

Soon will be listed here.

Abstract

A comparative study of the effects of BCG, Micrococcus lysodeikticus, and a series of structurally related polysaccharides (complement triggers) on the non-specific and specific immune resistance against L1210 lymphoid leukaemia was carried out and commented on. In contrast with authors of earlier reports, we were unable to generate any effective non-specific or specific immunotherapy after the graft of 10(4) leukaemic cells to 8--10-week-old CDF1 mice. However, when mice were prevaccinated with irradiated (8 krad X-rays) cultured cells combined with 1 mg of bacterium or polysaccharide one month before grafting 10(4) cells, they were given an immunoprotection that was more pronounced with the i.p. than with the i.v. route. Prevaccinated mice were afforded a stronger immunoprotection when boosted repeatedly with 1mg injections of bacterium or polysaccharide after tumour challenge.

Citing Articles

Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.

Verloes R, Atassi G, Dumont P, Kanarek L Br J Cancer. 1981; 43(2):201-9.

PMID: 7470382 PMC: 2010509. DOI: 10.1038/bjc.1981.29.

References

Old L, CLARKE D, Benacerraf B . Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959; 184(Suppl 5):291-2. DOI: 10.1038/184291a0. View

Johnson R, Houchens D, Gaston M, Goldin A . Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems. Cancer Chemother Rep. 1975; 59(4):697-705. View

SULTZER B . Infection with Bacillus Calmette-Guérin activates murine thymus-independent (B) lymphocytes. J Immunol. 1978; 120(1):254-61. View

Milas L, Scott M . Antitumor activity of Corynebacterium parvum. Adv Cancer Res. 1978; 26:257-306. DOI: 10.1016/s0065-230x(08)60090-1. View

Verloes R, de Ridder M, Kanarek L . Biochemical properties that accompany the production of homogeneous antibody response: a general mechanism hypothesis [proceedings]. Biochem Soc Trans. 1977; 5(4):1158-9. DOI: 10.1042/bst0051158. View

Mitchell M . Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications. Biomedicine. 1976; 24(4):209-13. View

Bianco C, Eden A, COHN Z . The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med. 1976; 144(6):1531-44. PMC: 2190471. DOI: 10.1084/jem.144.6.1531. View

Verloes R, Kanarek L, Atassi G . Antitumour immunoprotection by an immunobacterial lectin approach. Eur J Cancer (1965). 1976; 12(11):877-88. DOI: 10.1016/0014-2964(76)90005-0. View

Mansell P . Letter: Reactions to BCG. JAMA. 1973; 226(13):1570-1. DOI: 10.1001/jama.1973.03230130058031. View

10.

Hunt J, Silverstein M, Sparks F, Haskell C, PILCH Y, Morton D . Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet. 1973; 2(7833):820-1. DOI: 10.1016/s0140-6736(73)90860-x. View

11.

MATHE G, Kamel M, Dezfulian M, Bourut C . An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy. Cancer Res. 1973; 33(9):1987-97. View

12.

MATHE G, Pouillart P, LAPEYRAQUE F . Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer. 1969; 23(4):814-24. PMC: 2008494. DOI: 10.1038/bjc.1969.101. View

13.

Zbar B, Bernstein I, Rapp H . Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971; 46(4):831-9. View

14.

Ward P . A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med. 1967; 126(2):189-206. PMC: 2138318. DOI: 10.1084/jem.126.2.189. View

15.

Miller T, Mackaness G, Lagrange P . Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells. J Natl Cancer Inst. 1973; 51(5):1669-76. DOI: 10.1093/jnci/51.5.1669. View

16.

Pinsky C, Hirshaut Y, Oettgen H . Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr. 1973; 39:225-8. View

17.

Evans R, Alexander P . Mechanism of immunologically specific killing of tumour cells by macrophages. Nature. 1972; 236(5343):168-70. DOI: 10.1038/236168a0. View

18.

Sparks F, Silverstein M, Hunt J, Haskell C, PILCH Y, Morton D . Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973; 289(16):827-30. DOI: 10.1056/NEJM197310182891603. View

19.

Prehn R . The immune reaction as a stimulator of tumor growth. Science. 1972; 176(4031):170-1. DOI: 10.1126/science.176.4031.170. View

20.

Wolfe S, Tracey D, Henney C . Introduction of "natural" killer' cells by BCG. Nature. 1976; 262(5569):584-6. DOI: 10.1038/262584a0. View